Skip to content
High Tech Seed Founded 2022

Vevo Therapeutics

Provider of an in vivo drug discovery platform and AI models. The company uses a mosaic in vivo drug discovery platform and next-generation AI models for in vivo data generation, and single-cell precision, to capture in vivo context of disease and to represent patient diversity in drug response over current in vitro assays. The company was founded in 2022 and headquartered in San Francisco, United States. It has…

📍 San Francisco, United States · Generative AI,

Funding snapshot

Last roundSeed
Amount$12M
Date8 December 2022
Total raised$12M
Team size38

About

Provider of an in vivo drug discovery platform and AI models. The company uses a mosaic in vivo drug discovery platform and next-generation AI models for in vivo data generation, and single-cell precision, to capture in vivo context of disease and to represent patient diversity in drug response over current in vitro assays. The company was founded in 2022 and headquartered in San Francisco, United States. It has raised $12M in seed funding, with backing from Wing Venture Capital, General Catalyst, Mubadala, AIX Ventures, and others. The company operates in the High Tech - Generative AI, Native AI - Generative AI, HealthTech - Life Sciences Tech space.

Business model

Life Sciences Tech > Research & Development > Drug Informatics

Institutional investors

Wing Venture Capital General Catalyst Mubadala AIX Ventures Camford Capital

Latest coverage

No articles yet.

Raising like Vevo Therapeutics?

Analyze your pitch deck before your next raise.

Analyze My Deck →